BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 15645481)

  • 1. Long-term botulinum toxin efficacy, safety, and immunogenicity.
    Mejia NI; Vuong KD; Jankovic J
    Mov Disord; 2005 May; 20(5):592-7. PubMed ID: 15645481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections.
    Sankhla C; Jankovic J; Duane D
    Mov Disord; 1998 Jan; 13(1):150-4. PubMed ID: 9452341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemifacial spasm: results of treatment with low dose botulinum toxin injection.
    Suputtitada A; Phanthumchinda K; Locharernkul C; Suwanwela NC
    J Med Assoc Thai; 2004 Oct; 87(10):1205-11. PubMed ID: 15560699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.
    Factor SA; Molho ES; Evans S; Feustel PJ
    Mov Disord; 2005 Sep; 20(9):1152-60. PubMed ID: 15954134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of botulinum toxin therapy in otorhinolaryngology: experience from 1,000 treatments.
    Helmstaedter V; Wittekindt C; Huttenbrink KB; Guntinas-Lichius O
    Laryngoscope; 2008 May; 118(5):790-6. PubMed ID: 18300708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
    Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB
    Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study.
    Naumann M; Lowe NJ; Kumar CR; Hamm H;
    Arch Dermatol; 2003 Jun; 139(6):731-6. PubMed ID: 12810503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Frequency of side effects after botulinum toxin A injections in neurology, rehabilitation and gastroenterology].
    Sławek J; Madaliński MH; Maciag-Tymecka I; Duzyński W
    Pol Merkur Lekarski; 2005 Mar; 18(105):298-302. PubMed ID: 15997637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation.
    Thussu A; Barman CR; Prabhakar S
    Neurol India; 1999 Sep; 47(3):206-9. PubMed ID: 10514580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor.
    Wissel J; Masuhr F; Schelosky L; Ebersbach G; Poewe W
    Mov Disord; 1997 Sep; 12(5):722-6. PubMed ID: 9380055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of Botulinum toxin in classical achalasia: a prospective study.
    Kolbasnik J; Waterfall WE; Fachnie B; Chen Y; Tougas G
    Am J Gastroenterol; 1999 Dec; 94(12):3434-9. PubMed ID: 10606299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.
    Hsiung GY; Das SK; Ranawaya R; Lafontaine AL; Suchowersky O
    Mov Disord; 2002 Nov; 17(6):1288-93. PubMed ID: 12465070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot.
    Mancini F; Sandrini G; Moglia A; Nappi G; Pacchetti C
    Neurol Sci; 2005 Apr; 26(1):26-31. PubMed ID: 15877184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term treatment with botulinum toxin: dosage, treatment schedules and costs].
    Schnider P; Birner P; Moraru E; Auff E
    Wien Klin Wochenschr; 1999 Jan; 111(2):59-65. PubMed ID: 10081123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fast voluntary neck movements in patients with cervical dystonia: a kinematic study before and after therapy with botulinum toxin type A.
    Gregori B; Agostino R; Bologna M; Dinapoli L; Colosimo C; Accornero N; Berardelli A
    Clin Neurophysiol; 2008 Feb; 119(2):273-80. PubMed ID: 18063411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum A toxin treatment for blepharospasm and Meige syndrome: report of 100 patients.
    Poungvarin N; Devahastin V; Chaisevikul R; Prayoonwiwat N; Viriyavejakul A
    J Med Assoc Thai; 1997 Jan; 80(1):1-8. PubMed ID: 9078810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.
    Haussermann P; Marczoch S; Klinger C; Landgrebe M; Conrad B; Ceballos-Baumann A
    Mov Disord; 2004 Mar; 19(3):303-8. PubMed ID: 15022184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction.
    Akbar M; Abel R; Seyler TM; Bedke J; Haferkamp A; Gerner HJ; Möhring K
    BJU Int; 2007 Sep; 100(3):639-45. PubMed ID: 17532858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.